Trial Profile
An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil 9) in Solid Organ Transplant Recipients and HIV-infected Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 29 Dec 2020 Results assessing immunogenicity and safety of the 9vHPV vaccine HIV-infected persons and in SOT recipients, published in the Clinical Infectious Diseases
- 27 Jul 2020 Status changed from active, no longer recruiting to completed.
- 25 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.